# US 2003/0073655 A1 · Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073655 A1
- Document ID: US20030073655A1
- Status: Published application
- Kind: A1
- Application number: 10/084,380
- Filed: 2002-02-28
- Published: 2003-04-17
- Earliest claimed: 1997-04-09
- Assignees: Intellect Neurosciences Inc.
- Inventors: Daniel G. Chain
- Web page: https://patentgrep.com/patent/US20030073655A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- C12N 2799/025: where the vector is derived from a parvovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to β amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of treating a disease or a disorder, characterized by amyloid beta deposition. In another embodiment, the invention relates to an antibody molecule, which is free end-specific for the N-terminus or the C-terminus of an amyloid β peptide and to a pharmaceutical composition thereof. In another embodiment, the invention relates to an antibody molecule, which is targeted to the free C or N-terminus of a N-and/or C-terminus truncated amyloid β peptide fragment.

## Claims

### Claim 1

A method of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody which is targeted to amyloid β peptide, or to fragment thereof, thereby treating the subject having Alzheimer's Disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody is directed to amyloid β peptide, or fragment thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody is directed to N-terminus-truncated amyloid β peptide fragment.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is directed to C-terminus-truncated amyloid β peptide fragment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 7

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition, comprising the step of administering an antibody which is targeted to amyloid β peptide, or to fragment thereof, thereby treating the subject having disease or disorder characterized by amyloid beta deposition.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibody is directed to amyloid β peptide, or fragment thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antibody is directed to N-terminus-truncated amyloid β peptide fragment.

### Claim 10 (depends on 7)

The method of claim 7, wherein the antibody is directed to C-terminus-truncated amyloid β peptide fragment.

### Claim 11 (depends on 7)

The method of claim 7, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.

### Claim 12 (depends on 7)

The method of claim 7, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 13 (depends on 7)

The method of claim 7, wherein the disease or disorder characterized by amyloid beta deposition is mild cognitive impairment (MCI), cerebral amyloid angiopathy or congiophylic angiopathy, Alzheimer's disease associated with Down Syndrome, and inclusion-body myositis, and

### Claim 14

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering an antibody which is targeted to an amyloid β peptide, or to fragment thereof, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antibody is directed to amyloid β peptide, or fragment thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein the antibody is directed to N-terminus-truncated amyloid β peptide fragment.

### Claim 17 (depends on 14)

The method of claim 14, wherein the antibody is directed to C-terminus-truncated amyloid β peptide fragment.

### Claim 18 (depends on 14)

The method of claim 14, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.

### Claim 19 (depends on 14)

The method of claim 14, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 20

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering at antibody which is targeted to amyloid β peptide, or fragment thereof, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the antibody is directed to amyloid β peptide, or fragment thereof.

### Claim 22 (depends on 20)

The method of claim 20, wherein the antibody is directed to N-terminus-truncated amyloid β peptide fragment.

### Claim 23 (depends on 20)

The naethod of claim 20, wherein the antibody is directed to C-terminus-truncated amyloid β peptide fragment.

### Claim 24 (depends on 20)

The method of claim 20, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.

### Claim 25 (depends on 20)

The method of claim 20, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 26

An antibody that is free-end specific and is targeted to the free N-terminus of amyloid β-peptide.

### Claim 27 (depends on 26)

The antibody of claim 26, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 28

A antibody that is free-end specific and is targeted to the free N-terminus of amyloid β-peptide, wherein the first amino acid of amyloid β-peptide of said is aspartate.

### Claim 29 (depends on 28)

The antibody of claim 28, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 30

An antibody that is free-end specific and is targeted to the free N terminus of N and/or C-terminus-truncated amyloid β peptide fragment.

### Claim 31 (depends on 30)

The method of claim 30, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 32

An antibody that is free-end specific and is targeted to the free C-terminus of the amyloid β-peptide Aβ1-39, Aβ1-40, Aβ1-41, or Aβ1-43.

### Claim 33 (depends on 32)

The method of claim 32, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 34

An antibody that is free-end specific and is targeted to the free C-terminus of N- and/or C-terminus-truncated amyloid β peptide fragment.

### Claim 35 (depends on 34)

The antibody of claim 34, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

### Claim 36

A single chain or artifcial antibody that is free-end specific and is targeted to the free C-terminus of the amyloid β-peptide Aβ1-42.

### Claim 37 (depends on 26)

A pharmaceutical composition comprising an amount of the antibody of claim 26 and a pharmaceutical acceptable carrier.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intraperitoneally, intracerebrally, intranasally, orally, transdermally, buccally, intra-arterially, intaranially, or intracephalically.

### Claim 39 (depends on 28)

A pharmaceutical composition comprising an amount of the antibody of claim 28 and a pharmaceutical acceptable carrier.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intraperitoneally, intracerebrally, intranasally, orally, transdermally, buccally, intra-arterially, intracranially, or intracephalically.

### Claim 41 (depends on 30)

A pharmaceutical composition comprising an amount of the antibody of claim 30 and a pharmaceutical acceptable carrier.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intaperitoneally, intracerebrally, intranasally, orally, transdermally, buccally, intra-arterially, intracranially, or intracephalically.

### Claim 43 (depends on 32)

A pharmaceutical composition comprising an amount of the antibody of claim 32 and a pharmaceutical acceptable carrier.

### Claim 44 (depends on 43)

The pharmaceutical composition of claim 43, wherein the composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intraperitoneally, intracerebrally, intranasally, orally, transdermally, buccally, intra-arterially, intracranially, or intracephalically.

### Claim 45 (depends on 34)

A pharmaceutical composition comprising an amount of the antibody of claim 34 and a pharmaceutical acceptable carrier.

### Claim 46 (depends on 45)

The pharmaceutical composition of claim 45, wherein the composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intraperitoneally, intracerebrally, intranasally, orally, transdermally, buccally, intra-arterially, intracranially, or intracephalically.

### Claim 47 (depends on 36)

A pharmaceutical composition comprising an amount of the antibody of claim 36 and a pharmaceutical acceptable carrier.

### Claim 48 (depends on 47)

The pharmaceutical composition of claim 47, wherein the composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intraperitoneally, intracerebrally, intranasally, orally, transdermally, buccally, intra-arterially, intracranially, or intracephaically.

### Claim 49 (depends on 26)

A method of treating a subject having Alzheimer's Disease, comprising the step of administering the antibody of claim 26, thereby treating the subject having Alzheimer's Disease.

### Claim 50 (depends on 26)

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition comprising the step of administering the antibody of claim 26, thereby treating the subject having a disease or disorder characterized by amyloid beta deposition.

### Claim 51 (depends on 26)

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 26, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 52 (depends on 26)

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 26, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

### Claim 53 (depends on 28)

A method of treating a subject having Alzheimer's Disease, comprising the step of administering the antibody of claim 28, thereby treating the subject having Alzheimer's Disease.

### Claim 54 (depends on 28)

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition comprising the step of administering the antibody of claim 28, thereby treating the subject having a disease or disorder characterized by amyloid beta deposition.

### Claim 55 (depends on 28)

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 28, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 56 (depends on 28)

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 28, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

### Claim 57 (depends on 30)

A method of treating a subject having Alzheimer's Disease, comprising the step of administering the antibody of claim 30, thereby treating the subject having Alzheimer's Disease.

### Claim 58 (depends on 30)

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition comprising the step of administering the antibody of claim 30, thereby treating the subject having a disease or disorder characterized by amyloid beta deposition.

### Claim 59 (depends on 30)

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 30, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 60 (depends on 30)

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 30, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

### Claim 61 (depends on 32)

A method of treating a subject having Alzheimer's Disease, comprising the step of administering the antibody of claim 32, thereby treating the subject having Alzheimer's Disease.

### Claim 62 (depends on 32)

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition comprising the step of administering the antibody of claim 32, thereby treating the subject having a disease or disorder characterized by amyloid beta deposition.

### Claim 63 (depends on 32)

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 32, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 64 (depends on 32)

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 32, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

### Claim 65 (depends on 34)

A method of treating subject having Alzheimer's Disease, comprising the step of administering the antibody of claim 34, thereby treating the subject having Alzheimer's Disease.

### Claim 66 (depends on 34)

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition comprising the step of administering the antibody of claim 34, thereby treating the subject having a disease or disorder characterized by amyloid beta deposition.

### Claim 67 (depends on 34)

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 34, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 68 (depends on 34)

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 34, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

### Claim 69 (depends on 36)

A method of treating a subject having Alzheimer's Disease, and/or of treating a subject having other disease or disorder characterized by amyloid β deposition, comprising the step of administering the antibody of claim 36, thereby treating the subject having Alzheimer's Disease.

### Claim 70 (depends on 36)

A method of treating a subject having a disease or disorder characterized by amyloid beta deposition comprising the step of administering the antibody of claim 36, thereby treating the subject having a disease or disorder characterized by amyloid beta deposition.

### Claim 71 (depends on 36)

A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 36, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

### Claim 72 (depends on 36)

A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 36, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.
